Koneksa's digital biomarker platform uses best-in-class advanced algorithms to analyze and integrate real-time patient data in clinical trials from multiple wearables and sensors to create a single, seamless experience for patients, sponsors and research organizations.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 02/07/22 | $45,000,000 | Series C |
AyurMaya dRx Capital McKesson Ventures Merck Global Health Innovation Fund Takeda Ventures Velosity Capital Waterline Ventures | undisclosed |
